0.09 (1.03%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Strong
Earnings
Strong
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
BridgeBio Oncology Therapeutics, Inc.
Telephone
1.650.405.4770
Address
Suite 104, 256 East Grand Avenue, South San Francisco, CA 94080
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 7.6 - 14.87
Trade Value (12mth)
US$622,804.00
1 week
2.47%
1 month
-7.82%
YTD
-29.05%
1 year
-19.41%
All time high
14.87
EPS 3 yr Growth
2151850.00%
EBITDA Margin
0.00%
Operating Cashflow
-$114m
Free Cash Flow Return
-37.80%
ROIC
-44.50%
Interest Coverage
0.00
Quick Ratio
12.30
Shares Outstanding (Fully Diluted)
0m
HALO Sector
Other Finance
Next Company Report Date
05-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 13 May 26 | |
| 13 May 26 | |
| 13 May 26 | |
| 13 May 26 | |
| 30 April 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | N/A | -5,756.41 | -4.3 | | | | ||
EPS (Fully Diluted) | $ | | | | | N/A | -5,756.41 | -4.3 | | | | ||
Growth | % | | | | | -900 | -287,820,560.0 | 99.9 | | | | ||
PE | X | | | | | N/A | 32.5 | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
